Michael W Farrell

US Patent:

7481380, Jan 27, 2009

Filed:

Mar 22, 2005

Appl. No.:

11/086080

Inventors:

Frank Andrej Kvietok - Aurora CO, US
Elizabeth Ann Rohrbaugh - Hamilton OH, US
Michael Sean Farrell - Terrace Park OH, US

Assignee:

The Procter & Gamble Company - Cincinnati OH

International Classification:

B05B 1/28
A61L 9/04

US Classification:

239301, 239 6, 239 34, 239 43

Abstract:

A method for emitting or releasing volatile materials to the atmosphere is provided. More specifically, a method for delivering one or more volatile materials using a non-aerosol, non-energized volatile material delivery system via an evaporative surface device, without a source of heat, gas, or electrical current, are also provided.

US Patent:

7541455, Jun 2, 2009

Filed:

Dec 21, 2004

Appl. No.:

11/018897

Inventors:

Christopher Bieniarz - Tucson AZ, US
Michael Farrell - Tucson AZ, US
Jerome W. Kosmeder - Tucson AZ, US
Mark Lefever - Tucson AZ, US

Assignee:

Ventana Medical Systems, Inc. - Tucson AZ

International Classification:

C07H 21/02
C07H 21/04
C12Q 1/68

US Classification:

536 2626, 536 2623, 536 268, 435 6

Abstract:

A method for preparing a nucleic acid probe is provided. The method comprises forming an activated cytosine or cytidine by a bisulfite catalyzed reaction; and covalently linking a reporter molecule to the activated cytosine or cytidine, wherein said activating step, said covalently linking step, or both are conducted in the presence of microwave energy. Also provided by the invention are nucleic acid probes.

US Patent:

7642064, Jan 5, 2010

Filed:

Dec 20, 2004

Appl. No.:

11/015646

Inventors:

Christopher Bieniarz - Tucson AZ, US
Michael Farrell - Tucson AZ, US

Assignee:

Ventana Medical Systems, Inc. - Tucson AZ

International Classification:

C12Q 1/42
C12Q 1/44
C12Q 1/54
G01N 33/53
G01N 33/543
G01N 33/544
G01N 33/551

US Classification:

435 794, 435 71, 435 791, 435 14, 435 19, 435 21, 435188, 436503, 436514, 436518, 436524, 436528, 436164

Abstract:

The invention is directed to enhanced methods for detecting an analyte of interest in situ, by immunoassay, or by hybridization comprising binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion. The enzyme catalyzes the conversion of the inactive reductive species to an active reducing agent, which in turn reduces the metal ion to a metal atom thereby providing an enhanced means of detecting the analyte via metal deposition.

US Patent:

7682789, Mar 23, 2010

Filed:

May 4, 2007

Appl. No.:

11/800360

Inventors:

Xiao-Bo Chen - Tucson AZ, US
Christopher Bieniarz - Tucson AZ, US
Michael Farrell - Tucson AZ, US

Assignee:

Ventana Medical Systems, Inc. - Tucson AZ

International Classification:

C12Q 1/68
G01N 33/53
C07K 14/00
C07H 21/00
C07H 21/02
C07H 21/04

US Classification:

435 6, 435 71, 530350, 536 221, 536 231, 536 243

Abstract:

Disclosed embodiments concern quantifying a biomolecule conjugated to a nanoparticle. Quantifying typically comprises determining the number of biomolecules per nanoparticle. Any suitable biomolecule can be used, including but not limited to, amino acids, peptides, proteins, haptens, nucleic acids, oligonucleotides, DNA, RNA, and combinations thereof. A single type of biomolecule may be conjugated to the nanoparticle, more than one biomolecule of a particular class may be conjugated to the nanoparticle, or two or more classes of biomolecules may be conjugated to the nanoparticle. Certain disclosed embodiments comprise enzymatically or chemically digesting a biomolecule conjugated to the nanoparticle, or displacing a biomolecule using ligand-exchange chemistry. Where biomolecule concentrations are determined, any technique suitable for determining biomolecule concentration can be used, such as spectrophotometric techniques, including measuring tryptophan fluorescence and using a standard fluorescence intensity versus biomolecule concentration curve.

US Patent:

7695929, Apr 13, 2010

Filed:

Nov 1, 2007

Appl. No.:

11/982627

Inventors:

Jerome W. Kosmeder - Tucson AZ, US
Mark Lefever - Tucson AZ, US
Donald Johnson - Tucson AZ, US
Michael Farrell - Tucson AZ, US
Zhanna Zhilina - Oro Valley AZ, US
Christopher Bieniarz - Tucson AZ, US

Assignee:

Ventana Medical Systems, Inc. - Tucson AZ

International Classification:

G01N 33/53
C07K 16/00

US Classification:

435 794, 435 71, 435 792, 435961, 5303898, 5303913, 530807

Abstract:

A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.

US Patent:

8329401, Dec 11, 2012

Filed:

Oct 29, 2009

Appl. No.:

12/608261

Inventors:

Christopher Bieniarz - Tucson AZ, US
Michael Farrell - Tucson AZ, US

Assignee:

Ventana Medical Systems, Inc. - Tucson AZ

International Classification:

C12Q 1/68
C12M 1/00
C12M 1/34
C12M 3/00

US Classification:

435 61, 435 619, 4352831, 4352872

Abstract:

The invention is directed to enhanced methods for detecting an analyte of interest in situ, by immunoassay, or by hybridization comprising binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion. The enzyme catalyzes the conversion of the inactive reductive species to an active reducing agent, which in turn reduces the metal ion to a metal atom thereby providing an enhanced means of detecting the analyte via metal deposition.

US Patent:

8420798, Apr 16, 2013

Filed:

Aug 31, 2007

Appl. No.:

11/849060

Inventors:

Michael Farrell - Tucson AZ, US

Assignee:

Ventana Medical Systems, Inc. - Tucson AZ

International Classification:

C07H 21/04

US Classification:

536 243

Abstract:

The present disclosure provides nucleic acid probes, as well as kits that include such probes. Methods for producing and using (for example in chromosomal in situ hybridization) the probes are also provided. Such probes in some examples are used to detect chromosomal abnormalities or the presence of a pathogen.

US Patent:

8481270, Jul 9, 2013

Filed:

Aug 21, 2009

Appl. No.:

13/059274

Inventors:

Richard Gniewek - Oro Valley AZ, US
Michael Farrell - Tucson AZ, US
Hiroaki Nitta - Oro Valley AZ, US
Megan Lehrkamp - Castro Valley CA, US
Jerome Kosmeder - Tucson AZ, US
Brian Daniel Kelly - Tucson AZ, US
Thomas Grogan - Tucson AZ, US
Fabien Gaire - Oro Valley AZ, US
Mary Padilla - Tucson AZ, US
Christopher Bieniarz - Tucson AZ, US

Assignee:

Ventana Medical Systems, Inc. - Tucson AZ

International Classification:

C12Q 1/68
G01N 33/58
G01N 33/53

US Classification:

435 619, 435 61, 435 611, 435 617, 435 71, 435 79

Abstract:

The present invention provides a method and kit for detection of two or more target molecules in a single tissue sample, such as for gene and protein dual detection in a single tissue sample. Methods comprise treating a tissue sample with a first binding moiety that specifically binds a first target molecule. Methods further comprise treating the tissue sample with a solution containing a soluble electron-rich aromatic compound prior to or concomitantly with contacting the tissue sample with a hapten-labeled binding moiety and detecting a second target molecule. In one example, the first target molecule is a protein and the second is a nucleic acid sequence, the first target molecule being detected by immunohistochemistry and the second by in situ hybridization. The disclosed method reduces background due to non-specific binding of the hapten-labeled specific binding moiety to an insoluble electron rich compound deposited near the first target molecule.